Marta
Llanos Muñoz
Profesora Asociada Asistencial
Hospital General Universitario de Valencia
Valencia, EspañaPublicacions en col·laboració amb investigadors/es de Hospital General Universitario de Valencia (9)
2024
-
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651
2022
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2019
2017
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2003
-
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: A GEICAM-9801 phase II study
Breast Cancer Research and Treatment, Vol. 77, Núm. 1, pp. 1-8